| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT02778828 | Tuberculosis | Drug: Linezolid | Groupe Hospitalier Paris Saint Joseph | | 2015-12-10 | 2017-02-19 |
| NCT01224626 | Vancomycin Resistance Enterococcus Faecium | Drug: Zyvox (linezolid) | Pfizer | | 2006-05-01 | 2012-05-29 |
| NCT00625703 | Cystic Fibrosis | Drug: Linezolid | University of Texas Southwestern Medical Center|Cystic Fibrosis Foundation Therapeutics | Phase 2 | 2008-05-01 | 2009-01-21 |
| NCT01055769 | Healthy Volunteers | Drug: Linezolid|Drug: Linezolid | Pfizer | Phase 1 | 2010-03-01 | 2012-01-30 |
| NCT00691392 | Multi-Drug Resistant Tuberculosis|Extensively Drug Resistant Tuberculosis | Drug: Linezolid|Drug: Microcrystalline Methylcellulose - Placebo | Centers for Disease Control and Prevention|University of Texas|Columbia University|University of KwaZulu|University of Cape Town|Boston University|Pfizer | Phase 1|Phase 2 | 2009-04-01 | 2012-08-15 |
| NCT01200654 | Methicillin-Resistant Staphylococcus AureuS | Drug: Linezolid | University Hospital, Toulouse | Phase 4 | 2007-11-01 | 2012-10-22 |
| NCT01805284 | Pneumonia | Drug: Linezolid | University Ghent|University Hospital, Ghent|Pfizer | Phase 4 | 2013-02-01 | 2015-06-03 |
| NCT02269319 | Bacterial Infections | Drug: MRX-I|Drug: Linezolid | MicuRx | Phase 2 | 2015-02-01 | 2017-01-16 |
| NCT00359632 | Optic Nerve Diseases | Drug: Zyvox - linezolid|Drug: Matched control | Pfizer | Phase 3 | 2008-11-01 | 2015-06-03 |
| NCT00666276 | Staphylococcal Infections | Drug: linezolid (Zyvox) | Pfizer | | 2007-02-01 | 2012-05-29 |
| NCT00727844 | Pulmonary Tuberculosis|Multidrug Resistant Tuberculosis|Extensively Drug Resistant Tuberculosis | Drug: Immediate Start Linezolid|Drug: Delayed Start Linezolid | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 | 2008-07-01 | 2016-02-12 |
| NCT02877927 | Bacterial Infections|Skin Structures and Soft Tissue Infections | Drug: Omadacycline|Drug: Linezolid | Paratek Pharmaceuticals Inc | Phase 3 | 2016-08-01 | 2017-03-01 |
| NCT02378480 | Bacterial Infections|Skin Structures and Soft Tissue Infections | Drug: Omadacycline|Drug: Linezolid | Paratek Pharmaceuticals Inc | Phase 3 | 2015-06-01 | 2016-07-06 |
| NCT01170221 | Skin and Subcutaneous Tissue Bacterial Infections | Drug: TR-701 FA|Drug: Linezolid | Trius Therapeutics LLC | Phase 3 | 2010-08-01 | 2016-05-18 |
| NCT01561469 | Methicillin-Resistant Staphylococcus Aureus (MRSA)|Hospital-Acquired Pneumonia | Drug: Linezolid|Drug: Vancomycin | Pfizer|University of Louisville|Henry Ford Hospital|Summa Health System|Sparrow Health System|Jackson Health System | 2008-11-01 | 2014-06-09 |
| NCT00255996 | Burns | Drug: linezolid | Pfizer | Phase 1 | 2006-05-01 | 2009-07-13 |
| NCT00664313 | Multi-drug Resistant Tuberculosis|Extensively Drug Resistant Tuberculosis | Drug: Linezolid|Drug: Placebo | Centers for Disease Control and Prevention|University of KwaZulu|Columbia University|Yale University | Phase 1|Phase 2 | 2009-04-01 | 2012-10-01 |
| NCT01040585 | Ventilator Acquired Pneumonia | Drug: Linezolid | Pfizer | Phase 4 | 2010-07-01 | 2012-03-01 |
